These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25457750)

  • 1. “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!
    Burnouf T; Seghatchian J
    Transfus Apher Sci; 2014 Oct; 51(2):113-9. PubMed ID: 25457750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?
    Burnouf T; Faber JC; Radosevic M; Goubran H; Seghatchian J
    Transfus Apher Sci; 2020 Feb; 59(1):102715. PubMed ID: 31924526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product delivery in the developing world: options, opportunities and threats.
    Farrugia A
    Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern plasma fractionation.
    Burnouf T
    Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation-Report of an International Society of Blood Transfusion Workshop.
    Burnouf T; Epstein J; Faber JC; Smid M
    Vox Sang; 2022 Jun; 117(6):789-795. PubMed ID: 35262936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion-transmitted infection in hemophilia in developing countries.
    Yee TT; Lee CA
    Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Report on notifications pursuant to Section 21 German Transfusion Act for 2007].
    Henseler O; Heiden M; Haschberger B; Hesse J; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jul; 52(7):715-31. PubMed ID: 19572110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving perspectives in product safety for haemophilia.
    Farrugia A
    Haemophilia; 2002 May; 8(3):236-43. PubMed ID: 12010417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein therapies: current and future perspectives.
    Farrugia A; Robert P
    Best Pract Res Clin Haematol; 2006; 19(1):243-58. PubMed ID: 16377552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Firm behavior in the U.S. market for factor VIII: a need for policy?
    Nauenberg E; Sullivan SD
    Soc Sci Med; 1994 Dec; 39(12):1591-603. PubMed ID: 7846556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and supply of haemophilia products: worldwide perspectives.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research and development commitments in an integrated plasma collection and plasma fractionation environment.
    Radosevich M
    Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.